Cargando…
E3 Ubiquitin Ligase in Anticancer Drugdsla Resistance: Recent Advances and Future Potential
Drug therapy is the primary treatment for patients with advanced cancer. The use of anticancer drugs will inevitably lead to drug resistance, which manifests as tumor recurrence. Overcoming chemoresistance may enable cancer patients to have better therapeutic effects. However, the mechanisms underly...
Autores principales: | Liu, Yuanqi, Duan, Chaojun, Zhang, Chunfang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082683/ https://www.ncbi.nlm.nih.gov/pubmed/33935743 http://dx.doi.org/10.3389/fphar.2021.645864 |
Ejemplares similares
-
The Role of Membrane-Associated E3 Ubiquitin Ligases in Cancer
por: Chen, Xuankun, et al.
Publicado: (2022) -
E3-ubiquitin ligases and recent progress in osteoimmunology
por: Asano, Yosuke, et al.
Publicado: (2023) -
CHIP-mediated CIB1 ubiquitination regulated epithelial–mesenchymal transition and tumor metastasis in lung adenocarcinoma
por: Liu, Yuanqi, et al.
Publicado: (2020) -
CircRNAs in anticancer drug resistance: recent advances and future potential
por: Xu, Tianwei, et al.
Publicado: (2020) -
miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential
por: Yan, Hang, et al.
Publicado: (2022)